Free Trial

McKesson (MCK) Stock Forecast & Price Target

McKesson logo
$706.54 -6.25 (-0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$708.16 +1.62 (+0.23%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
13

Based on 16 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$681.00
-3.61% Downside
According to the 16 analysts' twelve-month price targets for McKesson, the average price target is $681.00. The highest price target for MCK is $805.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted downside of -3.61% from the current price of $706.54.
Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

Sign Up

MCK Analyst Ratings Over Time

TypeCurrent Forecast
5/1/24 to 5/1/25
1 Month Ago
4/1/24 to 4/1/25
3 Months Ago
2/1/24 to 1/31/25
1 Year Ago
5/2/23 to 5/1/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
13 Buy rating(s)
10 Buy rating(s)
Hold
3 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$681.00$649.36$646.14$536.71
Forecasted Upside-3.61% Downside-3.70% Downside8.62% Upside1.04% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-3.61% Downside3,373.19% Upside19.83% Upside
News Sentiment Rating
Positive News

See Recent MCK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/29/2025UBS Group
3 of 5 stars
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$708.00 ➝ $805.00+14.56%
4/11/2025Bank of America
3 of 5 stars
Michael Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$665.00 ➝ $755.00+11.34%
4/4/2025Cfra Research
0 of 5 stars
A. Sundaram
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
4/3/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Valiquette
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$630.00 ➝ $690.00-3.81%
4/2/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$642.00 ➝ $745.00+9.18%
3/14/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$641.00 ➝ $691.00+7.31%
2/6/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Elizabeth Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$650.00 ➝ $675.00+14.97%
1/10/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daniel Grosslight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$713.00 ➝ $677.00+15.15%
11/7/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$531.00 ➝ $688.00+25.25%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$665.00 ➝ $630.00+29.78%
9/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$623.00 ➝ $579.00+20.99%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00+19.54%
8/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$596.00 ➝ $616.00+12.78%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$570.00 ➝ $670.00+11.10%
5/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$563.00 ➝ $652.00+19.74%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$450.00 ➝ $485.00+11.71%
5/9/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:23 PM ET.


Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 22, 2025. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • The current stock price is around $697, reflecting a strong market position and potential for growth.
  • Recent upgrades from major analysts, including a price target increase to $755, indicate positive market sentiment and confidence in the company's future performance.
  • McKesson Co. has a solid dividend yield of 0.41%, providing investors with a steady income stream, which is particularly attractive in uncertain market conditions.
  • The company has received a majority of buy ratings from analysts, suggesting strong confidence in its operational performance and growth prospects.
  • With a market capitalization of approximately $87.38 billion, McKesson Co. is well-positioned to leverage its scale for competitive advantages in the healthcare sector.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • Recent insider selling, including significant shares sold by the CEO, may raise concerns about the company's future outlook and management's confidence in its performance.
  • The stock has experienced fluctuations, with a 1-year low of $464.42, indicating potential volatility that could deter risk-averse investors.
  • Despite positive ratings, there are still three analysts who have rated the stock as a hold, suggesting some uncertainty about its short-term performance.
  • The company's dividend payout ratio is relatively low at 13.00%, which may indicate limited growth in dividend payments in the near future.
  • Market conditions and potential economic downturns could impact the healthcare sector, affecting McKesson Co.'s revenue and profitability.

MCK Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $681.00, with a high forecast of $805.00 and a low forecast of $579.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted downside of -3.61% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 downgrade by analysts.

McKesson has been rated by research analysts at Bank of America, Cfra Research, Evercore ISI, Mizuho, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how MCK compares to other companies.


This page (NYSE:MCK) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners